Phase I Study of Pasireotide (SOM230) in Combination With RAD001 in Patients With Advanced Neuroendocrine Tumours.
Phase of Trial: Phase I
Latest Information Update: 21 Oct 2016
At a glance
- Drugs Everolimus (Primary) ; Pasireotide (Primary) ; Pasireotide (Primary)
- Indications Neuroendocrine carcinoma
- Focus Adverse reactions
- 18 Oct 2016 Status changed from active, no longer recruiting to completed.
- 12 Apr 2016 Planned End Date changed from 1 Oct 2014 to 1 Oct 2016.
- 28 Apr 2014 Planned End Date changed from 1 Oct 2013 to 1 Oct 2014 as reported by ClinicalTrials.gov record.